JP2006516949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516949A5 JP2006516949A5 JP2004536551A JP2004536551A JP2006516949A5 JP 2006516949 A5 JP2006516949 A5 JP 2006516949A5 JP 2004536551 A JP2004536551 A JP 2004536551A JP 2004536551 A JP2004536551 A JP 2004536551A JP 2006516949 A5 JP2006516949 A5 JP 2006516949A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- methionine
- alkyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 120
- 239000008194 pharmaceutical composition Substances 0.000 claims 66
- 230000035772 mutation Effects 0.000 claims 47
- 108020004705 Codon Proteins 0.000 claims 45
- 101700011961 DPOM Proteins 0.000 claims 45
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 45
- 101710029649 MDV043 Proteins 0.000 claims 45
- 101700061424 POLB Proteins 0.000 claims 45
- 101700054624 RF1 Proteins 0.000 claims 45
- 150000002148 esters Chemical class 0.000 claims 45
- 239000000651 prodrug Substances 0.000 claims 45
- 229940002612 prodrugs Drugs 0.000 claims 45
- 150000003839 salts Chemical class 0.000 claims 45
- 239000011780 sodium chloride Substances 0.000 claims 45
- 239000004474 valine Substances 0.000 claims 45
- 125000002252 acyl group Chemical group 0.000 claims 39
- 125000000539 amino acid group Chemical group 0.000 claims 38
- 239000003937 drug carrier Substances 0.000 claims 37
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 33
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 33
- 229910052739 hydrogen Inorganic materials 0.000 claims 33
- 239000000546 pharmaceutic aid Substances 0.000 claims 32
- 150000002431 hydrogen Chemical class 0.000 claims 30
- 239000001257 hydrogen Substances 0.000 claims 30
- 230000001629 suppression Effects 0.000 claims 30
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims 27
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 27
- 235000011178 triphosphate Nutrition 0.000 claims 27
- 239000001226 triphosphate Substances 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 26
- 239000003814 drug Substances 0.000 claims 26
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 24
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims 24
- 229940079593 drugs Drugs 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 18
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 15
- 230000001747 exhibiting Effects 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 108010050904 Interferons Proteins 0.000 claims 12
- 102000014150 Interferons Human genes 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- 229940079322 interferon Drugs 0.000 claims 12
- -1 L-valinyl Chemical group 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 5
- 102100008763 IFNA2 Human genes 0.000 claims 4
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 3
- 108010047761 Interferon-alpha Proteins 0.000 claims 3
- 102000006992 Interferon-alpha Human genes 0.000 claims 3
- 229910005965 SO 2 Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- 150000003212 purines Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 claims 3
- ZLCOWUKVVFVVKA-UHFFFAOYSA-N 3-[(2-acetamido-2-carboxyethyl)disulfanyl]-2-aminopropanoic acid Chemical compound CC(=O)NC(C(O)=O)CSSCC(N)C(O)=O ZLCOWUKVVFVVKA-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- WOZSCQDILHKSGG-UHFFFAOYSA-N Preveon Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 claims 2
- GWFOVSGRNGAGDL-FSDSQADBSA-N 2-amino-9-[(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutyl]-3H-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1C[C@H](CO)[C@H]1CO GWFOVSGRNGAGDL-FSDSQADBSA-N 0.000 claims 1
- CKTSBUTUHBMZGZ-CHKWXVPMSA-N 4-amino-1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 CKTSBUTUHBMZGZ-CHKWXVPMSA-N 0.000 claims 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 claims 1
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N Clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 claims 1
- QDGZDCVAUDNJFG-FXQIFTODSA-N Entecavir Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)C1=C QDGZDCVAUDNJFG-FXQIFTODSA-N 0.000 claims 1
- 229960002963 Ganciclovir Drugs 0.000 claims 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N Ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 claims 1
- 101700046422 IFNA Proteins 0.000 claims 1
- 101700011451 IFNB1 Proteins 0.000 claims 1
- 102100015720 IFNB1 Human genes 0.000 claims 1
- 101700023446 IFNT Proteins 0.000 claims 1
- 229940090438 Infergen Drugs 0.000 claims 1
- PBJNZCQJMWVIRT-MDQYBHOLSA-N Inosine pranobex Chemical compound CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C2=NC=NC(O)=C2N=C1 PBJNZCQJMWVIRT-MDQYBHOLSA-N 0.000 claims 1
- 108090000467 Interferon beta Proteins 0.000 claims 1
- 102000003996 Interferon beta Human genes 0.000 claims 1
- 108010005716 Interferon beta-1a Proteins 0.000 claims 1
- 229960004461 Interferon beta-1a Drugs 0.000 claims 1
- 229940028862 Interferon gamma-1b Drugs 0.000 claims 1
- 229960001388 Interferon-beta Drugs 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000008070 Interferon-gamma Human genes 0.000 claims 1
- 229920002459 Intron Polymers 0.000 claims 1
- 229950005339 LOBUCAVIR Drugs 0.000 claims 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims 1
- 229940002988 Pegasys Drugs 0.000 claims 1
- 229940106366 Pegintron Drugs 0.000 claims 1
- 229940038850 Rebif Drugs 0.000 claims 1
- 229960000329 Ribavirin Drugs 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-CSMHCCOUSA-N Telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 claims 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N Tenofovir Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 claims 1
- 229960004556 Tenofovir Drugs 0.000 claims 1
- RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 claims 1
- 229960001997 adefovir Drugs 0.000 claims 1
- 229960003130 interferon gamma Drugs 0.000 claims 1
- 108010042414 interferon gamma-1b Proteins 0.000 claims 1
- 108010045648 interferon omega 1 Proteins 0.000 claims 1
- 229960001614 levamisole Drugs 0.000 claims 1
- 229960001179 penciclovir Drugs 0.000 claims 1
- DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 claims 1
- 0 CC(C)[C@@](C(OC[C@](C(CO)C1)O[C@@]1N1C=CC(*)=NC1O)=O)N Chemical compound CC(C)[C@@](C(OC[C@](C(CO)C1)O[C@@]1N1C=CC(*)=NC1O)=O)N 0.000 description 5
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41067502P | 2002-09-13 | 2002-09-13 | |
| PCT/US2003/029017 WO2004024095A2 (en) | 2002-09-13 | 2003-09-15 | ß-L-2'-DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008099992A Division JP2008273960A (ja) | 2002-09-13 | 2008-04-08 | 耐性ＨＢＶ菌株の治療のためのβ−Ｌ−２’−デオキシヌクレオシド及び併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516949A JP2006516949A (ja) | 2006-07-13 |
| JP2006516949A5 true JP2006516949A5 (US20040097461A1-20040520-C00002.png) | 2006-11-02 |
| JP4173861B2 JP4173861B2 (ja) | 2008-10-29 |
Family
ID=31994179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004536551A Expired - Fee Related JP4173861B2 (ja) | 2002-09-13 | 2003-09-15 | 耐性ＨＢＶ菌株の治療のためのβ−Ｌ−２’−デオキシヌクレオシド及び併用療法 |
| JP2008099992A Pending JP2008273960A (ja) | 2002-09-13 | 2008-04-08 | 耐性ＨＢＶ菌株の治療のためのβ−Ｌ−２’−デオキシヌクレオシド及び併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008099992A Pending JP2008273960A (ja) | 2002-09-13 | 2008-04-08 | 耐性ＨＢＶ菌株の治療のためのβ−Ｌ−２’−デオキシヌクレオシド及び併用療法 |
Country Status (14)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| DE60022665T2 (de) * | 1999-09-25 | 2006-06-22 | Coley Pharmaceutical Gmbh | Immunstimulierende nukeinsäuren |
| US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
| HUE027522T2 (en) * | 2002-09-13 | 2016-11-28 | Novartis Ag | ß-L-2'-Deoxynucleosides for treatment of resistant HBV strains and for combination therapies |
| US20040235770A1 (en) * | 2003-04-02 | 2004-11-25 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations and related methods of use |
| RU2358979C2 (ru) | 2003-05-30 | 2009-06-20 | Фармассет, Инк. | Модифицированные фторированные аналоги нуклеозида |
| US20070167353A1 (en) * | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
| CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| KR101177590B1 (ko) * | 2004-09-14 | 2012-08-27 | 파마셋 인코포레이티드 | 2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조 |
| CA2600036A1 (en) * | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
| BRPI0614863A2 (pt) * | 2005-08-15 | 2011-04-19 | Hoffmann La Roche | uso de conjugados de peg-ifn-alfa em associação a ribavirina, bem como kit compreendendo os mesmos |
| JP2010513484A (ja) * | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｒｎａ依存性ｒｎａウイルス感染治療用ヌクレオシド環状ホスホロアミデート |
| WO2008106167A1 (en) * | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases |
| BRPI0808089A2 (pt) * | 2007-02-28 | 2014-07-15 | Conatus Pharmaceuticals Inc | Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c. |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| US20090082306A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telbivudine |
| US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| KR20110104074A (ko) | 2008-12-23 | 2011-09-21 | 파마셋 인코포레이티드 | 퓨린 뉴클레오시드의 합성 |
| PA8855601A1 (es) | 2008-12-23 | 2010-07-27 | Forformidatos de nucleósidos | |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
| CA2794671C (en) | 2010-03-31 | 2018-05-01 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
| WO2012075140A1 (en) | 2010-11-30 | 2012-06-07 | Pharmasset, Inc. | Compounds |
| CN102140534A (zh) * | 2010-12-15 | 2011-08-03 | 深圳华大基因科技有限公司 | 一种hbv基因的核苷酸突变位点的检测方法 |
| KR102055331B1 (ko) | 2011-04-21 | 2019-12-12 | 아이오니스 파마수티컬즈, 인코포레이티드 | B형 간염 바이러스(hbv) 발현 조절 |
| CN106166160A (zh) | 2011-09-16 | 2016-11-30 | 吉利德制药有限责任公司 | 用于治疗hcv的组合物 |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| US9415065B2 (en) * | 2012-04-04 | 2016-08-16 | University Of Central Florida Research Foundation, Inc. | Methods of using cerium oxide nanoparticles to mitigate or protect against radiation injury |
| US20140212491A1 (en) | 2013-01-31 | 2014-07-31 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| US9688666B2 (en) * | 2013-02-07 | 2017-06-27 | Tobira Therapeutics, Inc. | Lamivudine salts |
| EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| JP6912100B2 (ja) | 2016-11-16 | 2021-07-28 | 国立研究開発法人国立国際医療研究センター | 抗ウイルス活性等の生理活性を有するヌクレオシド誘導体 |
| EP3596202A4 (en) | 2017-03-14 | 2021-01-27 | The Regents of the University of California | GENOME-WIDE IDENTIFICATION OF IMMUNEVASIONAL FUNCTIONS IN A VIRUS |
| US11446303B2 (en) | 2019-06-21 | 2022-09-20 | Tosk, Inc. | Uridine phosphorylase (UPase) inhibitors for treatment of liver conditions |
| CN115607532A (zh) * | 2021-07-15 | 2023-01-17 | 上海市公共卫生临床中心 | 大黄酸在制备改善老年机体免疫功能药物中的应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4916122A (en) | 1987-01-28 | 1990-04-10 | University Of Georgia Research Foundation, Inc. | 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition |
| US5190926A (en) | 1987-01-28 | 1993-03-02 | University Of Georgia Research Foundation, Inc. | 3'-azido-2',3'-dideoxypyrimidines and related compounds as antiviral agents |
| GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| JPH03501253A (ja) | 1987-09-22 | 1991-03-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | エイズ（ａｉｄｓ）治療を目的とするリポソームによるヌクレオシド類似物質 |
| US6020322A (en) | 1993-11-09 | 2000-02-01 | Pro-Neuron, Inc. | Acyl deoxyribonucleoside derivatives and uses thereof |
| DE3855513T2 (de) | 1987-10-28 | 1997-01-09 | Pro Neuron Inc | Acyl deoxyribonukleosid-derivate und deren verwendungen |
| SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| JPH05507279A (ja) | 1990-05-29 | 1993-10-21 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | グリセロールジ―およびトリホスフェート誘導体の合成 |
| DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
| US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| IT1246983B (it) | 1990-11-13 | 1994-12-12 | Consiglio Nazionale Ricerche | L-2'-desossiuridine e composizioni farmaceutiche che le contengono. |
| IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
| PT100198B (pt) | 1991-03-06 | 2000-03-31 | Univ Emory | Utilizacao de nucleosido oxatiolano para a preparacao de composicoes para fins terapeuticos |
| WO1992018517A1 (en) | 1991-04-17 | 1992-10-29 | Yale University | Method of treating or preventing hepatitis b virus |
| EP0594677A4 (en) | 1991-07-12 | 1997-09-17 | Vical Inc | Antiviral liponucleosides: treatment of hepatitis b |
| US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
| EP0691981A1 (en) | 1993-03-10 | 1996-01-17 | The Wellcome Foundation Limited | Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides |
| JP3693357B2 (ja) | 1993-04-09 | 2005-09-07 | 峯郎 実吉 | 逆転写酵素阻害剤 |
| AU701574B2 (en) | 1993-05-12 | 1999-02-04 | Karl Y. Hostetler | Acyclovir derivatives for topical use |
| WO1995007086A1 (en) | 1993-09-10 | 1995-03-16 | Emory University | Nucleosides with anti-hepatitis b virus activity |
| US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
| WO1996011204A1 (de) | 1994-10-07 | 1996-04-18 | Max-Delbrück-Centrum für Molekulare Medizin | NEUE β-L-NUCLEOSIDE UND IHRE VERWENDUNG |
| US5559101A (en) | 1994-10-24 | 1996-09-24 | Genencor International, Inc. | L-ribofuranosyl nucleosides |
| US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
| WO1996040164A1 (en) | 1995-06-07 | 1996-12-19 | Emory University | Nucleosides with anti-hepatitis b virus activity |
| AT409815B (de) | 1995-07-11 | 2002-11-25 | Enco En Componenten Ges M B H | Anlage zur aufbereitung biogener rohstoffe |
| US6025335A (en) | 1995-09-21 | 2000-02-15 | Lipitek International, Inc. | L-Nucleoside Dimer Compounds and therapeutic uses |
| US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| WO1999066936A1 (en) | 1998-06-24 | 1999-12-29 | Emory University | Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv |
| JP3959176B2 (ja) | 1998-06-25 | 2007-08-15 | 松下電器産業株式会社 | ファンモータ駆動装置 |
| AU5475799A (en) * | 1998-08-10 | 2000-03-06 | Centre National De La Recherche Scientifique | Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis |
| US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
| US6065181A (en) * | 1998-09-03 | 2000-05-23 | Cleveland; Thomas | Portable ticket scratching device with vacuum |
| AR028149A1 (es) | 1999-07-08 | 2003-04-30 | Innogenetics Nv | Deteccion de la resistencia a los farmacos contra la hepatitis b |
| US6265181B1 (en) | 1999-09-24 | 2001-07-24 | The Public Health Research Institute Of The City Of New York, Inc. | Dosing and development of antimicrobial and antiviral drugs determined by restriction of resistant mutant selection |
| DE60105424T2 (de) * | 2000-05-26 | 2005-09-22 | Idenix (Cayman) Ltd. | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden |
| MY141594A (en) * | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
| US6875751B2 (en) | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
| WO2002000613A2 (en) * | 2000-06-27 | 2002-01-03 | Axxima Pharmaceuticals Ag | Inhibitors of hepatitis b virus infection |
| US6855346B2 (en) * | 2001-10-05 | 2005-02-15 | Tzu-Sheng Wu | Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same |
| HUE027522T2 (en) * | 2002-09-13 | 2016-11-28 | Novartis Ag | ß-L-2'-Deoxynucleosides for treatment of resistant HBV strains and for combination therapies |
-
2003
- 2003-09-15 HU HUE03770334A patent/HUE027522T2/en unknown
- 2003-09-15 ES ES03770334.5T patent/ES2547002T3/es not_active Expired - Lifetime
- 2003-09-15 DK DK03770334.5T patent/DK1572095T3/en active
- 2003-09-15 BR BR0314259-0A patent/BR0314259A/pt not_active Application Discontinuation
- 2003-09-15 KR KR1020057004375A patent/KR100855907B1/ko active IP Right Grant
- 2003-09-15 EP EP03770334.5A patent/EP1572095B1/en not_active Expired - Lifetime
- 2003-09-15 SI SI200332444T patent/SI1572095T1/sl unknown
- 2003-09-15 JP JP2004536551A patent/JP4173861B2/ja not_active Expired - Fee Related
- 2003-09-15 CN CNB038251159A patent/CN100536853C/zh not_active Expired - Lifetime
- 2003-09-15 AU AU2003278816A patent/AU2003278816A1/en not_active Abandoned
- 2003-09-15 US US10/662,641 patent/US7186700B2/en not_active Expired - Lifetime
- 2003-09-15 WO PCT/US2003/029017 patent/WO2004024095A2/en active Search and Examination
- 2003-09-15 CA CA2498731A patent/CA2498731C/en not_active Expired - Lifetime
- 2003-09-15 KR KR1020087012404A patent/KR20080053419A/ko not_active Application Discontinuation
- 2003-09-15 PT PT37703345T patent/PT1572095E/pt unknown
-
2007
- 2007-01-09 US US11/651,353 patent/US7928086B2/en not_active Expired - Fee Related
-
2008
- 2008-04-08 JP JP2008099992A patent/JP2008273960A/ja active Pending
-
2011
- 2011-03-21 US US13/052,750 patent/US8158606B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516949A5 (US20040097461A1-20040520-C00002.png) | ||
| CA2498731A1 (en) | .beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies | |
| US8895531B2 (en) | 2′-fluoronucleoside phosphonates as antiviral agents | |
| JP2004513070A5 (US20040097461A1-20040520-C00002.png) | ||
| Mahmoud et al. | Antiviral nucleoside and nucleotide analogs: a review | |
| JP4294870B2 (ja) | Ｂ型肝炎の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド | |
| KR101508018B1 (ko) | 바이러스 감염의 치료를 위한 화합물 및 제약 조성물 | |
| US6815542B2 (en) | Nucleoside compounds and uses thereof | |
| CN103403014B (zh) | O-(经取代的苯甲基)氨基磷酸酯化合物及其治疗用途 | |
| JP6860585B2 (ja) | 非環状抗ウイルス 優先出願の参照による組み込み | |
| US20090156545A1 (en) | Substituted Phosphate Esters of Nucleoside Phosphonates | |
| WO2014124430A1 (en) | Nucleotide and nucleoside therapeutic compositions and uses related thereto | |
| CN1416431A (zh) | 核苷化合物及其应用 | |
| Zhou et al. | β-D-2′-C-methyl-2, 6-diaminopurine ribonucleoside phosphoramidates are potent and selective inhibitors of hepatitis C virus (HCV) and are bioconverted intracellularly to bioactive 2, 6-diaminopurine and guanosine 5′-triphosphate forms | |
| US20050119286A1 (en) | Beta-2'-or 3'-halonucleosides | |
| JP2005503358A5 (US20040097461A1-20040520-C00002.png) | ||
| CN1233254A (zh) | 嘌呤l－核苷、其类似物及其用途 | |
| JP2004533401A5 (US20040097461A1-20040520-C00002.png) | ||
| CA2904692A1 (en) | Modified 4'-nucleosides as antiviral agents | |
| JP2004513070A (ja) | β−Ｌ−２’−デオキシヌクレオシドを用いたデルタ型肝炎ウイルス感染の処置方法 | |
| EA020244B1 (ru) | Урацильные циклопропилнуклеотиды | |
| WO1996022778A1 (en) | Derivatives of succinamide and their use as metalloproteinase inhibitor | |
| RU2005118421A (ru) | 2'-разветвленные нуклеозиды и мутация flaviviridae | |
| JP2011246469A (ja) | Ｂ型肝炎ウイルス活性を持ったヌクレオシド | |
| JP2008255121A (ja) | 抗ｂ型肝炎ウイルス活性を有するヌクレオシド |
